Core Viewpoint - Harbin Pharmaceutical Group announced the approval of its oral solution of ferric succinate for the treatment of iron deficiency anemia by the National Medical Products Administration of China [1][3] Group 1: Product Approval - The oral solution of ferric succinate is a non-prescription drug used to treat iron deficiency anemia caused by insufficient iron intake, absorption issues, chronic blood loss, and conditions during pregnancy and lactation [1] - As of the announcement date, there are a total of 10 domestic drug approval numbers and 1 import drug approval number for the oral solution of ferric succinate [1] Group 2: Sales Projections - According to the Minet database, the projected annual sales for the oral solution of ferric succinate in domestic hospitals for 2024 is approximately 626.2 million yuan, with sales of 490.34 million yuan for the first three quarters of 2025 [1] - The Zhongkang database indicates that the projected retail sales for the oral solution of ferric succinate in 2024 is around 114 million yuan, with sales of 83 million yuan for the first three quarters of 2025 [1] Group 3: R&D Investment - The company has invested approximately 4.851 million yuan in research and development for the oral solution of ferric succinate project as of the announcement date (unaudited) [2]

Core Viewpoint - The company is planning to acquire control of Luoyang Fengrui Fluorine Industry Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds [1] Group 1: Acquisition Details - The company's stock will be suspended from trading starting January 29, 2026, with an expected suspension period of no more than 10 trading days [1] - The company is actively advancing the transaction and is in communication and negotiation with relevant parties regarding the transaction plan [1] - The transaction is still in the planning stage, and no formal agreement has been signed yet [1] Group 2: Approval and Uncertainty - The transaction requires approval from the company's board of directors, shareholders, and relevant regulatory authorities before it can be officially implemented [1] - There is uncertainty regarding the final implementation of the transaction [1]

吉宏股份公告，控股股东、实际控制人庄浩将其860万股于2024-04-26质押、质权人为中国银河证券股 份有限公司的股份于2026-02-02解除质押，占其所持股份12.93%、占公司总股本1.91%。截至公告日， 庄浩持股6650.31万股，持股比例14.77%，已质押2200万股，占其所持股份33.08%、占公司总股本 4.88%。 ...

1月29日，最后一场活动由济南新星公司收官。济南新星凭借其渠道运营能力与市场口碑，成为品牌连 接本地消费者的重要枢纽。本场活动最终达成销售额150万元。 三场活动累计销售额突破510万元，整体超出预期。 1月27日，首场活动由济南稼轩酒业承办。现场融合传统年味与茅台酱香酒文化，嘉宾回顾既往合作， 共商新年规划。活动当晚实现销售额超240万元。 1月28日，山东一区与渤翔酒业共同举办第二场答谢会。活动设置专业品鉴环节，嘉宾深入感受茅台酱 香酒的工艺与风味，进一步理解其文化内涵与市场价值。本场活动实现销售额120万元。 近日，茅台酱香芳华官方公众号发布"济南三场新春答谢会圆满举办，茅台酱香酒累计销售额突破510万 元"的消息。当中披露，近日，酱香酒公司山东一区联合济南稼轩酒业有限公司、山东渤翔酒业有限公 司、济南新星名酒销售有限公司三家核心经销商，在济南连续举办三场新春答谢会。 ...

2月3日，广发银行发布公告称，该行于2025年10月28日召开第十届董事会第二十次会议，聘任林朝晖为行长；2025年11月25日，广发银行召开2025年第四次 临时股东大会，选举林朝晖为董事。同日，第十届董事会第二十一次会议选举林朝晖为董事长，任期均与第十届董事会同期。 近日，广发银行收到《国家金融监督管理总局关于林朝晖广发银行董事、副董事长、行长任职资格的批复》（金复﹝2026﹞65号）。根据该批复，国家金融 监督管理总局已核准林朝晖担任该行董事、副董事长、行长的任职资格，其任职自2026年1月30日起生效。 ...

据Zegna(杰尼亚)集团在2025年初步业绩显示，全年营收19.17亿欧元，同比下滑1.5%；固定汇率下有机 增长1.1%。第四季度营收5.91亿欧元，同比增长0.3%，固定汇率下有机销售额增长4.6%。 (杰尼亚集团财报) 渠道表现：DTC渠道全年营收14.49亿欧元，同比增长4.2%，固定汇率下有机增长7.9%，占整体营收比 重达82%；批发渠道营收3.18亿欧元，同比下降20.9%。第四季度DTC渠道有机收入同比增长约10%。 区域市场：美洲市场销售额5.661亿欧元，同比增长7.9%；EMEA市场销售额6.83亿欧元，同比增长 0.5%；大中华区收入4.35亿欧元，同比下滑14.6%。 分品牌业绩：ZEGNA主线全年营收11.82亿欧元，同比增长1.5%，固定汇率下有机增长4.7%；Tom Ford Fashion全年营收3.17亿欧元，同比增长0.8%；Thom Browne全年收入2.68亿欧元，同比大跌14.7%。 ...

据国泰航空大湾区内地城市春运出行数据显示，截至2月初的订票数据，2026年春运期间国泰航空整体 订票表现较2025年春运期间显著提升。 大湾区内地与中国香港之间的出行需求增长显著。2026年春运期间，大湾区内地赴中国香港旅客预定量 同比增长超过80%，整体需求表现强劲。 其中，广州航线在春运期间旅客订票量实现同比双位数增长。这主要得益于航班班次的增加，旅客出行 便利度进一步提升。新增的第三班广州—香港航班(CX953)有效缩短了转机时间，拓展了更多出行选 择，进一步释放市场需求。春运期间，深圳、广州、上海、北京是国泰航空在内地的主要客源城市。 (国泰航空) 整体来看，2026年春运期间，国泰航空旅客订票量同比增长超过20%，客座位运载量同比增加超过 15%，反映节日期间出行需求持续向好。 从客源结构和航线表现看，春运期间短途航线中，新加坡、首尔、曼谷最受旅客欢迎；长途航线方面， 悉尼、洛杉矶、纽约及墨尔本需求旺盛。 ...

康方授权济川在合作期限内，拥有康方自主开发并已获批上市的伊努西单抗注射液的独家商业化权益。 济川向康方支付8000万元（含税）授权费，并支付最高不超过人民币1000万元（含税）的里程碑付款。 近日，济川药业（600566）发布公告称，公司全资子公司济川药业集团有限公司、江苏济源医药有限公 司（以下合称"济川"）与中山康方生物医药有限公司、康融东方（广东）医药有限公司（以下合称"康 方"）签署独占性商业化权益协议。 ...

Group 1 - The core idea is that Alibaba International Station, in collaboration with Cainiao, has introduced a one-stop management service for foreign trade merchants, allowing them to continue receiving orders during the Chinese New Year while automating the shipping process [1][6] - Merchants can participate in the "Spring Festival No Shutdown" activity by completing two steps: signing up and pre-storing goods in the warehouse, enabling them to manage their operations with minimal involvement [1] - The initiative aims to transform the traditionally slow sales period during the Spring Festival into a "cross-border golden week" by ensuring stable logistics through the establishment of emergency response centers nationwide [6] Group 2 - Alibaba International Station has launched a "three-free policy," which includes waiving collection fees, operation fees, and storage fees, allowing merchants to store goods at zero cost [6] - Products registered under this initiative will receive enhanced visibility through dedicated traffic pools and special exposure during the Spring Festival, marked with labels like "24-hour dispatch" and "Fastshipping" to reassure overseas buyers [6] - Early results show significant increases in store traffic and order placements, with one company reporting a 60% increase in visitors and another securing two orders within a day after marking products with the "24-hour dispatch" label [6]

记者从多位产业链人士处获悉，马斯克团队近期"摸底"中国光伏产业链，已有异质结设备厂签单。据知 情人士称，近期马斯克旗下的SPACE X团队和Tesla团队"摸底"中国光伏企业，其中TESLA团队目前仅 是验厂阶段，到访多家产业链企业；SPACE X团队主要到访光伏设备厂，并与国内某头部异质结设备厂 有订单合作，但基于商业保密要求等因素，未作公开。有企业人士对记者记者表示，目前能整线供应异 质结设备的企业较少，此前马斯克团队曾向国内某异质结企业稳定采购，且合作还在持续。(智通财经) ...